Meeting
2020 ASCO Virtual Scientific Program
EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435).
Authors
Li-Tzong Chen
National Health Research Institutes, Tainan, Taiwan
Li-Tzong Chen , Muh-Hwan Su
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT03126435
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS4669)
DOI
10.1200/JCO.2020.38.15_suppl.TPS4669
Abstract #
TPS4669
Poster Bd #
277
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
A single-center experience of modified FOLFOX-6 in locally advanced and metastatic pancreatic adenocarcinomas.
First Author: Bradley Sumrall
Poster
2019 Gastrointestinal Cancers Symposium
FOLFIRINOX in pancreatic cancer patients age 75 years or older.
First Author: Jonathan Mizrahi
Poster
2018 Gastrointestinal Cancers Symposium
Retrospective single center review of toxicity and efficacy of a modified FOLFIRINOX regimen in patients with locally advanced and metastatic pancreatic cancer.
First Author: Bhargavi Pulluri
Poster
2015 ASCO Annual Meeting
Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.
First Author: Alix Portal